In 2014, Saito and colleagues developed the AppNL-G-F AD mouse model with the goal to overcome one of the major disadvantages of the transgenic AD mouse models which are characterized by the overexpression of the amyloid precursor protein (APP) controlled by an exogenous promoter. This evidence concerns the gene APP and Alzheimer disease.